SOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present an update on the company and its programs at two upcoming healthcare investor conferences.
SVB Leerink Global Healthcare Conference
Date & Location: Wednesday, February 27, 2019, New York City
Presentation Time: 1:50 p.m. – 2:10 p.m. EST
Cowen's 39th Annual Health Care Conference
Date & Location: Tuesday, March 12, 2019, Boston
Presentation Time: 9:30 a.m. – 9:55 a.m. EDT
About Pliant Therapeutics
Pliant Therapeutics is a clinical stage biotechnology company targeting the key biological pathways driving fibrosis. Pliant has leveraged its powerful product discovery engine to develop a portfolio of novel therapeutics that seek to halt progression of multiple life-threatening fibrotic diseases. The company's lead product candidate, PLN-74809, is a selective inhibitor of αvβ1 and αvβ6 integrin receptors that play a key role in multiple fibrotic pathways. PLN-74809 has received Orphan Designation from the FDA in both idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and is being studied in an ongoing Phase 1 clinical trial. Pliant's second product candidate, PLN-1474, is a selective inhibitor of αvβ1, targeting late-stage liver fibrosis and is currently in IND-enabling studies. For more information, please visit www.pliantrx.com.
Media Contact:
Cambria Fuqua
Canale Communications
(619) 849-5390
cambria@canalecomm.com
SOURCE Pliant Therapeutics, Inc.
